Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine in Hospitalized Adults with RSV
NCT02935673Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of lumicitabine in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Oct 2016; status: terminated.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02935673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935673.